NRXP (NRX Pharmaceuticals) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NRX Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2024 was $-2.31 Mil. NRX Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, NRX Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, NRX Pharmaceuticals's current FCF Yield % is -29.51%.

The historical rank and industry rank for NRX Pharmaceuticals's FCF Margin % or its related term are showing as below:

NRXP's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -144.19
* Ranked among companies with meaningful FCF Margin % only.

NRX Pharmaceuticals FCF Margin % Historical Data

The historical data trend for NRX Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals FCF Margin % Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of NRX Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, NRX Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NRX Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's FCF Margin % falls into.

NRX Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NRX Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-21.66	/	0
	=	%

NRX Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-2.306	/	0
	=	%

NRX Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

B1Q:Germany

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Executives

Jonathan C Javitt	director, 10 percent owner, officer: Chief Scientist	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz	director	C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard	director, officer: Chief Executive Officer	1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt	10 percent owner	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg	officer: Chief Financial Officer	C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof	officer: Chief Comm. & Patient Officer	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault	officer: General Counsel & Secretary	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster	director	C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
William Fricker	officer: CFO & Treasurer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Big Rock Partners Sponsor, Llc	10 percent owner	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Richard Ackerman	director, 10 percent owner, officer: President & CEO	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483